



MelNet update

20 March 2019

MelNet Skin Lesion and Dermatoscopy Courses

MelNet is currently offering two Skin Lesion and Dermatoscopy courses. Conducted by Adjunct Associate Professor Amanda Oakley, these one-day courses will address clinical and dermatoscopic diagnosis of common benign and malignant skin lesions, particularly pigmented lesions.

All health professionals undertaking skin examinations are invited to attend, whether new to or experienced in dermatoscopy.

Last chance to register for the Goodfellow/MelNet course

10.00 am – 5.00 pm

Friday 22 March 2019

Vodafone Events Centre, Auckland

Registrations close 21 March 2019 – don't miss your chance to attend. This course has been endorsed by The Royal New Zealand College of General Practitioners and has been approved for up to 6.0 credits CME for General Practice Educational Programme Stage 2 (GPEP2) and Maintenance of Professional Standards (MOPS) purposes.

[Register](#) | [More information](#) | [Course programme](#)

Registrations now open for New Plymouth course

9.00 am – 5.00 pm

Saturday 11 May 2019

The Devon Hotel, New Plymouth

This course is hosted by MelNet with support from the Health Promotion Agency. It has been endorsed by The Royal New Zealand College of General Practitioners and has been approved for up to 6.5 credits CME for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes.

[Register](#) | [More information](#) | [Course programme](#)

Roche Translational Cancer Research Fellowship

This award provides a unique opportunity for NZ cancer research teams to up-skill an integral team member so that the team can work together more effectively to improve research output.

Translational research teams that include BOTH clinicians and scientists are eligible for this award, valued at \$30,000. The team must all be New Zealand Society for Oncology (NZSO) members and will be required to give an oral presentation at a subsequent NZSO conference describing the use of the support provided by the award, learning gained and how this has impacted on the research team.

Applications will be assessed by a panel consisting of two senior international cancer researchers and chaired ex officio by the President of the NZSO.

To apply please send the CV of the team recipient, along with a one page proposal that includes details on the team, how the team proposes to use the funds and how the proposed activity would improve the output of the team to charlotte@conference.nz. All applications must be received by **Friday 30 August**.

[Full details on eligibility, favoured recipients and requirements](#)

Review of ‘Standards of Service Provision for Melanoma Patients in New Zealand – Provisional’ underway

The Ministry of Health is working alongside the sector to replace provisional tumour standards with a new Standard of Care for People Affected by Cancer. The purpose of the new Standard of Care is to support:

- national consistency in access to treatment
- equity of outcomes
- system integration
- a shift to people-centered (as opposed to health system centered) care.

A National Melanoma Tumour Standards Working Group has been formed to update the provisional 2013 Melanoma Standards and identify quality performance indicators to drive service improvements. Members of the working group represent key specialties across the melanoma pathway of care, and many were involved in the development of the provisional Melanoma Standards.

Consultation with key sector stakeholders will be undertaken throughout the review.

[More information](#)

Announcement: ANZMTG incorporated as Melanoma and Skin Cancer Trials Limited



Melanoma and Skin Cancer Trials (MASC Trials) is a new not-for-profit company that currently comprises the previous Executive Committee of the (former) Australia and New Zealand Melanoma Trials Group (ANZMTG). Closely aligned line with the original aims of ANZMTG and according to a new constitution, MASC Trials has been established to:

- facilitate, design, conduct, analyse, publish and promote research, particularly clinical trials in melanoma and non-melanoma skin cancer
- develop and advance the scientific basis of research, particularly clinical trials
- collaborate with people, groups, companies and bodies as appropriate to pursue these objectives
- foster optimal patient care through development and maintenance of standards and through clinical research including clinical trials.

This exciting development in the melanoma and skin cancer field has been necessitated by the dramatically and rapidly increasing complexity and breadth of collaborations and trials in this field. The governance structure provided by MASC Trials will offer improved performance and recruitment within investigator-initiated melanoma and skin cancer trials. The incorporated legal status of MASC Trials will help researchers create, set up, and deliver clinical trials and other research in a maximally efficient and supportive manner, fast-tracking trial recruitment and research outcomes for patients.

Automatic transfer of members to MASC Trials has been completed. New members are always welcome (it's free to join) – please email admin@masc.org.au. A new MASC Trials website will be coming soon.

MelNet and MASC Trials look forward to continuing to collaborate and partner in the delivery of improved outcomes for patients and families affected by melanoma and skin cancer.

MASC Trials Executive Committee

Professor Mark Shackleton (Chair); Melbourne, Victoria, Australia

Professor Andrew Spillane (Deputy Chair); Sydney, New South Wales, Australia

Paul White (Company Secretary); Melbourne, Victoria, Australia

Professor Gerald Fogarty; Sydney, New South Wales, Australia

Dr Donna Milne; Melbourne, Victoria, Australia

Associate Professor Victoria Mar; Melbourne, Victoria, Australia

Associate Professor Anne Cust; Sydney, New South Wales, Australia

Professor Peter Soyer; Brisbane, Queensland, Australia

Dr Richard Martin; Auckland, New Zealand

Professor Michael Millward; Perth, Western Australia, Australia

Skin Cancer College Australasia reach 1000 members

Congratulations to the Skin Cancer College Australasia who have reached a major milestone of more than 1,000 active members.

“The Skin Cancer College Australasia exists to foster and support the development of health care professionals in their goal to combat skin cancer and save lives. We’re extremely passionate and proud of the work we have done with registered doctors, nurses, specialists, researchers and students via education, research, advocacy and standards.”

– Lynette Hunt, CEO Skin Cancer College Australasia

The Skin Cancer College Australasia offers a comprehensive skin cancer education pathway, starting at Certificate level and progressing to Advanced Clinical Certificate qualifications, accreditation and Fellowship. College members also gain access to the “Skin Cancer Blog”, a skin cancer clinical discussion forum.

Upcoming events



> Certificate of Skin Cancer Medicine
> Certificate of Dermoscopy

AUCKLAND:
13 – 14 April 2019

DON'T MISS OUT!

CLICK HERE to register now or to view a full list of course dates and locations.

SKIN CANCER COLLEGE AUSTRALASIA

Certificate of Skin Cancer Medicine

13 – 14 April 2019

Auckland

For GPs wanting to expand their knowledge and skills relating to the safe practice of skin cancer medicine. The course covers techniques for diagnosis including clinical examination, assessing risk factors for skin cancer, basic dermoscopy and biopsy. Both surgical and non-surgical management options are explored including elliptical surgery and basic suturing techniques.

[Register](#)

Certificate of Dermoscopy

13 – 14 April 2019

Auckland

An introduction to dermoscopy suitable for doctors and nurses wanting to understand the basics of this skin cancer diagnostic technique. This interactive programme focuses on diagnosis of pigmented and non-pigmented lesions and explores various diagnostic algorithms.

[More information](#) | [Register](#)

Other upcoming events

April	May
<p>World Congress on Advanced Treatments and Technologies in Skin Cancer 4 – 5 April 2019 Vienna, Austria Further information</p>	<p>Inaugural Australasian Ocular Melanoma Alliance (AOMA) Summit 3 - 4 May 2019 Sydney, Australia Further information</p>
<p>National Rural Health Conference 2019 4 – 7 April 2019 Blenheim Further information</p>	<p>Royal Australasian College of Surgeons 88th Annual Scientific Congress 2019 6 – 10 May 2019 Bangkok, Thailand Further information</p>
<p>Professional Certificate of Skin Cancer Medicine 6 – 7 April 2019 Adelaide Further information</p>	<p>Australasian College of Dermatologists Annual Scientific Meeting 2019 18 – 21 May 2019 Melbourne, Australia Further information</p>
<p>Advanced Skin Surgery Workshop 12 – 15 April 2019 Auckland Further information</p>	<p>9th Australasian Skin Cancer Congress 24 – 26 May 2019 Gold Coast, Australia Further information</p>
<p>15th European Association of Dermato Oncology (EADO) Congress 24 – 27 April 2019 Paris, France Further information</p>	<p>For more events see the MelNet events calendar</p>

Recent MelNet website postings

[Sun-protection programmes with new technologies have potential to increase sun protection behaviours](#)

[Upper limb isolated limb infusion safe and effective](#)

[Immunotherapy impacts quality of life of patients and carers](#)

[New Zealander's advised to apply sunscreen every day](#)

[Glembatumumab vedotin acceptable for advanced melanoma patients resistant to checkpoint inhibitors and MEK/BRAF inhibition](#)

[Patients more willing to pay for combination immunotherapy than BRAF/MEK inhibitors due to overall survival expectations](#)

[Histopathology diagnoses of thin melanoma compared to dysplastic naevi inconsistent](#)

[YOVAL1.1 melanoma model valuable platform to guide combined targeted therapy and immunotherapy approaches in BRAFV600E melanoma](#)

[MELPREDICT useful in predicting CDKN2A mutations in patients from melanoma-prone families.](#)

[Skin cancer screening has important primary prevention function](#)
